Moderna shares jump 7.1% on cancer vaccine pipeline progress

Moderna shares jumped 7.1% in the afternoon session on 17 September 2026 after the company presented at the Morgan Stanley Global Healthcare Conference. The stock rose to $155.56 per share as investor sentiment improved around the firm's vaccine pipeline.

Investor focus centered on clinical and regulatory developments reported by TipRanks. Optimism was led by ongoing progress in the Phase 3 trial of intismeran, Moderna's personalized cancer vaccine candidate. Sentiment was also boosted by momentum and new regulatory approvals in its respiratory portfolio.

The stock has experienced high volatility, recording 57 moves greater than 5% over the past year. Just six days earlier, the shares rose 8.5% amid a broader market rotation into defensive healthcare assets. Morningstar reported that macro conditions helped lift the sector index by approximately 7% quarter to date, reaching a 5% valuation premium.

Moderna is up 404% since the start of the year. However, its price of $155.56 remains 10.8% below its 52-week high of $174.38 set in August 2026. A $1,000 investment in Moderna shares made five years ago would currently be worth $361.71.